• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket

    4/1/24 8:08:35 AM ET
    $APLT
    $AVTX
    $CLSK
    $CURV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLT alert in real time by email

    Shares of Doma Holdings Inc. (NYSE:DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash.

    Doma Holdings shares jumped 34.1% to $6.09 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Vast Renewables Limited (NASDAQ:VSTE) rose 213.9% to $9.70 in pre-market trading after jumping 39% on Thursday.
    • MediaCo Holding Inc. (NASDAQ:MDIA) gained 84% to $0.9601 in pre-market trading after dipping more than 17% on Thursday.
    • Galera Therapeutics, Inc. (NASDAQ:GRTX) gained 49.5% to $0.2093 in pre-market trading. Galera Therapeutics posted fourth-quarter results on Thursday.
    • Qilian International Holding Group Limited (NASDAQ:QLI) shares gained 32.2% to $0.8399 in pre-market trading.
    • Sunshine Biopharma, Inc. (NASDAQ:SBFM) gained 30.7% to $0.0791 in pre-market trading after the company reported operating results for the fiscal year ended Dec. 31, 2023.
    • Xilio Therapeutics, Inc. (NASDAQ:XLO) shares rose 26.8% to $1.37 in pre-market trading. Xilio Therapeutics shares jumped 69% on Thursday after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program.
    • Zapata Computing Holdings Inc. (NASDAQ:ZPTA) gained 10.3% to $15.01 in pre-market trading.
    • Torrid Holdings Inc. (NYSE:CURV) shares rose 13.9% to $5.5579 in pre-market trading after the company reported better-than-expected fourth-quarter financial results.
    • PAVmed Inc. (NASDAQ:PAVM) climbed 8% to $2.31 in pre-market trading after dipping over 20% on Thursday.


    Losers

    • Mountain Crest Acquisition Corp. IV (NASDAQ:MCAF) fell 58.7% to $5.99 pre-market trading. CH Auto Technology and Mountain Crest Acquisition Corp. IV completed transformative business combination.
    • Fractyl Health, Inc. (NASDAQ:GUTS) declined 28.9% to $5.26 in pre-market trading after the company received FDA IDE approval for Revita Remain-1 study for obesity after discontinuation of GLP-1 based drugs. The company also reported fourth-quarter results.
    • ENDRA Life Sciences Inc. (NASDAQ:NDRA) shares dropped 28.3% to $0.4157 in pre-market trading after the company reported fourth-quarter results.
    • X3 Holdings Co Ltd. (NASDAQ:XTKG) fell 28.1% to $0.7118 in pre-market trading after the company unveiled its strategic partnership with a leading provider of semiconductor modules and devices..
    • Sintx Technologies, Inc. (NASDAQ:SINT) fell 22.8% to $0.0382 in pre-market trading after announcing a proposed public offering of common stock.
    • Vivos Therapeutics, Inc. (NASDAQ:VVOS) fell 18.8% to $3.9220 pre-market trading after reporting quarterly results.
    • Avalo Therapeutics, Inc. (NASDAQ:AVTX) fell 16.4% to $18.19 in pre-market trading following FY2023 results.
    • Applied Therapeutics, Inc. (NASDAQ:APLT) shares tumbled 14.7% to $5.80 in pre-market trading after the company announced that the FDA extended the review period for the NDA for govorestat for the treatment of Classic Galactosemia by three months.
    • CleanSpark, Inc. (NASDAQ:CLSK) shares fell 12.3% to $18.60 in pre-market trading after declining over 8% on Thursday. Cantor Fitzgerald analyst Josh Siegler maintained Cleanspark with an Overweight and raised the price target from $10 to $20 on Thursday.
    • Oxford Industries, Inc. (NYSE:OXM) fell 6% to $105.68 in pre-market trading as the company reported downbeat financial results for its fourth quarter and issued weak guidance for the first quarter.

     

    Now Read This: Top 2 Energy Stocks That Are Preparing To Pump In April

     

    Get the next $APLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLT
    $AVTX
    $CLSK
    $CURV

    CompanyDatePrice TargetRatingAnalyst
    Oxford Industries Inc.
    $OXM
    3/27/2026$40.00 → $36.00Market Perform
    Telsey Advisory Group
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Fractyl Health Inc.
    $GUTS
    1/30/2026$2.00Overweight → Equal-Weight
    Morgan Stanley
    CleanSpark Inc.
    $CLSK
    1/13/2026$22.50Outperform
    Northland Capital
    Oxford Industries Inc.
    $OXM
    1/13/2026$35.00 → $40.00Market Perform
    Telsey Advisory Group
    CleanSpark Inc.
    $CLSK
    1/8/2026$22.00Buy
    Maxim Group
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Applied Therapeutics Inc.
    $APLT
    12/12/2025Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $APLT
    $AVTX
    $CLSK
    $CURV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $APLT
    $AVTX
    $CLSK
    $CURV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports Fourth Quarter and Full-Year Fiscal 2025 Results

    Initiates fiscal 2026 guidance reflecting meaningfully improved profitability on modest sales growth driven by improvement at Tommy Bahama.Fiscal 2026 guidance includes revenues of $1.475 billion to $1.530 billion, GAAP EPS of $1.83 to $2.43 and adjusted EPS of $2.10 to $2.70; EPS expectations assume IEEPA tariff rates continued for balance of year.Increases quarterly dividend to $0.70 per share. ATLANTA, March 26, 2026 (GLOBE NEWSWIRE) -- Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its fourth quarter and full fiscal year 2025 ended January 31, 2026 and initiated guidance for the first quarter and full fiscal year 2026. Consolidated net sales in the fourth qu

    3/26/26 4:05:00 PM ET
    $OXM
    Garments and Clothing
    Industrials

    MediaCo Audio Delivers Strong February Ratings Growth Across Key Markets

    MediaCo Holding Inc. (NASDAQ:MDIA) today announced a strong February performance across its audio portfolio, with audience growth in key dayparts and demos driving momentum in New York, Southern California, Dallas-Fort Worth, and Houston. New York led by HOT 97 and WBLS, with HOT 97 rising to #4 in mornings and #3 in afternoons, and Prime AQH up 41% year over year. WBLS posted 35% afternoon AQH growth among Persons 25-54 and strong weekend gains. Southern California delivered one of MediaCo's strongest books, powered by Que Buena (KBUE) in Los Angeles, which saw double-digit AQH growth and major morning gains, and 96.1 KRQB, which posted standout increases including 200% midday growth a

    3/26/26 9:32:00 AM ET
    $MDIA
    Broadcasting
    Consumer Discretionary

    Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

    Insurance Coverage on Vivos Appliances and Treatment Now Available to a Significant Number of Nevada Patients Previously Unable to Access Coverage Concurrently, Vivos Implements Cost Reduction Initiatives Related to Legacy Business Model to Focus on Scaling its Medical Affiliation Distribution Model LITTLETON, Colo., March 26, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (OSA), today announced that physician-owned professional entities supported by t

    3/26/26 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $APLT
    $AVTX
    $CLSK
    $CURV
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by CleanSpark Inc.

    SCHEDULE 13G/A - CLEANSPARK, INC. (0000827876) (Subject)

    3/26/26 5:12:48 PM ET
    $CLSK
    Finance: Consumer Services
    Finance

    Oxford Industries Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OXFORD INDUSTRIES INC (0000075288) (Filer)

    3/26/26 4:10:50 PM ET
    $OXM
    Garments and Clothing
    Industrials

    ENDRA Life Sciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)

    3/25/26 9:21:26 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APLT
    $AVTX
    $CLSK
    $CURV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on Oxford Industries with a new price target

    Telsey Advisory Group reiterated coverage of Oxford Industries with a rating of Market Perform and set a new price target of $36.00 from $40.00 previously

    3/27/26 7:58:08 AM ET
    $OXM
    Garments and Clothing
    Industrials

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fractyl Health downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Fractyl Health from Overweight to Equal-Weight and set a new price target of $2.00

    1/30/26 6:42:49 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $APLT
    $AVTX
    $CLSK
    $CURV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Schultz S. Matthew

    4 - CLEANSPARK, INC. (0000827876) (Issuer)

    3/24/26 8:18:21 PM ET
    $CLSK
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Vecchiarelli Gary Anthony

    4 - CLEANSPARK, INC. (0000827876) (Issuer)

    3/24/26 8:17:17 PM ET
    $CLSK
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Monnig Taylor

    4 - CLEANSPARK, INC. (0000827876) (Issuer)

    3/24/26 8:16:19 PM ET
    $CLSK
    Finance: Consumer Services
    Finance

    $APLT
    $AVTX
    $CLSK
    $CURV
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results

    XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Plan to present new preclinical data at AACR for potential first-in-class masked T cell engager program targeting CLDN18.2 Extended cash runway through the end of 2027 WALTHAM, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced pipeline progress and busin

    3/23/26 7:30:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MediaCo Appoints Armando Diaz as Vice President, Operations & Efficiency

    MediaCo Holding Inc. (NASDAQ:MDIA) today announced the appointment of Armando Diaz as Vice President, Operations & Efficiency. Diaz will report to Brian Fisher, Chief Revenue Officer of MediaCo. In this role, Diaz will focus on strengthening operational discipline across the organization, simplifying internal processes, and driving sustainable expansion in support of the company's EBITDA growth strategy. Diaz brings more than 20 years of corporate leadership experience, including senior roles within media and broadcast organizations where he has led complex operational environments and cross-functional teams. Throughout his career, he has driven efficiency and transformation initiatives

    3/16/26 8:00:00 AM ET
    $MDIA
    Broadcasting
    Consumer Discretionary

    $APLT
    $AVTX
    $CLSK
    $CURV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Vast Renewables Limited

    SC 13D/A - Vast Renewables Ltd (0001964630) (Subject)

    12/16/24 8:59:53 PM ET
    $VSTE
    Building Products
    Industrials

    SEC Form SC 13G filed by Torrid Holdings Inc.

    SC 13G - Torrid Holdings Inc. (0001792781) (Subject)

    12/12/24 6:06:52 PM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Vast Renewables Limited

    SC 13D/A - Vast Renewables Ltd (0001964630) (Subject)

    11/27/24 6:49:39 PM ET
    $VSTE
    Building Products
    Industrials

    $APLT
    $AVTX
    $CLSK
    $CURV
    Financials

    Live finance-specific insights

    View All

    Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports Fourth Quarter and Full-Year Fiscal 2025 Results

    Initiates fiscal 2026 guidance reflecting meaningfully improved profitability on modest sales growth driven by improvement at Tommy Bahama.Fiscal 2026 guidance includes revenues of $1.475 billion to $1.530 billion, GAAP EPS of $1.83 to $2.43 and adjusted EPS of $2.10 to $2.70; EPS expectations assume IEEPA tariff rates continued for balance of year.Increases quarterly dividend to $0.70 per share. ATLANTA, March 26, 2026 (GLOBE NEWSWIRE) -- Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its fourth quarter and full fiscal year 2025 ended January 31, 2026 and initiated guidance for the first quarter and full fiscal year 2026. Consolidated net sales in the fourth qu

    3/26/26 4:05:00 PM ET
    $OXM
    Garments and Clothing
    Industrials

    Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Processed 3,664 EsoGuard® tests and recognized 4Q25 revenue of $1.5 millionExpanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world experience of esophageal precancer detectionConference call and webcast to be held today, March 26, at 8:30 AM ESTNEW YORK, March 26, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full

    3/26/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

    Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026 Received favorable FDA feedback on De Novo classification request; De Novo submission expected in late Q4 2026 Reports new post-hoc analyses from REMAIN-1 Midpoint Cohort showing statistically significant ablation-length (i.e., dose)-dependent treatment effect on post-GLP-1 weight maintenance at 6 months Patients with greater GLP-1-induced weight loss prior to randomization also exhibited larger sham-adjusted treatment effects at 6 months, with effect size increasing over time New analyses provide further support for Revita mechanism of action and REMAIN-1 Pivotal Cohort design Reiterates

    3/24/26 4:01:00 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care